These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24635127)

  • 41. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer.
    Arai N; Sasaki H; Tamura R; Ohara K; Yoshida K
    World Neurosurg; 2017 Nov; 107():1047.e9-1047.e15. PubMed ID: 28804045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
    Li J; Gu J
    Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
    Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX; Cleck JN
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
    Grünwald V; Heinzer H; Fiedler W
    Onkologie; 2007 Oct; 30(10):519-24. PubMed ID: 17890892
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Sikic D; Lüdecke G; Lieb V; Keck B
    Urologe A; 2016 May; 55(5):648-52. PubMed ID: 27119958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
    Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sunitinib-induced thyrotoxicosis - a not so rare entity.
    Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
    Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.
    Basille D; Andrejak M; Bentayeb H; Kanaan M; Fournier C; Lecuyer E; Boutemy M; Garidi R; Douadi Y; Dayen C
    Ann Pharmacother; 2010 Feb; 44(2):383-6. PubMed ID: 20118139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A; Staehler M; Eames T
    Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
    Wuthrick EJ; Kamrava M; Curran WJ; Werner-Wasik M; Camphausen KA; Hyslop T; Axelrod R; Andrews DW; Glass J; Machtay M; Dicker AP
    Cancer; 2011 Dec; 117(24):5548-59. PubMed ID: 21647871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
    Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.